000137690 001__ 137690
000137690 005__ 20240229105115.0
000137690 0247_ $$2doi$$a10.1080/23723556.2015.1074335
000137690 0247_ $$2pmid$$apmid:30250876
000137690 0247_ $$2pmc$$apmc:PMC6150047
000137690 037__ $$aDKFZ-2018-01567
000137690 041__ $$aeng
000137690 082__ $$a610
000137690 1001_ $$0P:(DE-He78)ce86d7d02a229acfaca4b63f01a1171b$$aMatt, Sonja$$b0$$eFirst author$$udkfz
000137690 245__ $$aCrosstalk between p53 modifiers at PML bodies.
000137690 260__ $$aLondon$$bTaylor & Francis$$c2018
000137690 3367_ $$2DRIVER$$aarticle
000137690 3367_ $$2DataCite$$aOutput Types/Journal article
000137690 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1538728627_31301
000137690 3367_ $$2BibTeX$$aARTICLE
000137690 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000137690 3367_ $$00$$2EndNote$$aJournal Article
000137690 520__ $$aTumor protein p53 (TP53, best known as p53), the most frequently mutated tumor suppressor in cancer, plays a central role in cell fate decisions induced by DNA damage. Regulation of p53 activity by post-translational modifications has been linked to promyelocytic leukemia nuclear bodies (PML-NBs), where p53 encounters many of its regulators. Recent evidence implies that crosstalk between p53 regulators at the PML-NB shapes post-translational modifications and function of p53.
000137690 536__ $$0G:(DE-HGF)POF3-311$$a311 - Signalling pathways, cell and tumor biology (POF3-311)$$cPOF3-311$$fPOF III$$x0
000137690 588__ $$aDataset connected to CrossRef, PubMed,
000137690 7001_ $$0P:(DE-He78)99ae95278bd95e30462a4fb2d12026c6$$aHofmann, Thomas$$b1$$eLast author$$udkfz
000137690 773__ $$0PERI:(DE-600)2835425-4$$a10.1080/23723556.2015.1074335$$gVol. 5, no. 3, p. e1074335 -$$n3$$pe1074335 -$$tMolecular & cellular oncology$$v5$$x2372-3556$$y2018
000137690 909CO $$ooai:inrepo02.dkfz.de:137690$$pVDB
000137690 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ce86d7d02a229acfaca4b63f01a1171b$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000137690 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)99ae95278bd95e30462a4fb2d12026c6$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000137690 9131_ $$0G:(DE-HGF)POF3-311$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vSignalling pathways, cell and tumor biology$$x0
000137690 9141_ $$y2018
000137690 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000137690 9201_ $$0I:(DE-He78)A210-20160331$$kA210$$lZelluläre Seneszenz$$x0
000137690 980__ $$ajournal
000137690 980__ $$aVDB
000137690 980__ $$aI:(DE-He78)A210-20160331
000137690 980__ $$aUNRESTRICTED